Kornimate/medical-research-clean huggingface dataset:
km110329 in adult patients with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine clinical efficacy and safety of km110329 for atopic dermatitis.

a randomized, double blind, placebo-controlled, multicenter trial will be conducted at the seoul st.mary's hospital, at chung-ang university hospital, and at kyung hee university hospital at gangdong. participants fulfilling eligibility criteria will be selected. enrolled participants will be randomly allocated to two parallel groups: the km110329 and placebo arms. each participant will be examined for signs and symptoms of atopic dermatitis before and after taking functional food.

Eligibility criteria:
inclusion criteria: * men and women ages 18 to 65 years * individuals who diagnosed atopic dermatitis according to the criteria of hanifin and rajka * individuals who mild to moderate atopic dermatitis (objective scorad≤40) * written informed consent for participation in the trial exclusion criteria: * severe skin disease other than atopic dermatitis * secondary infection with bacteria, fungi, and virus * uncontrolled hypertension (sbp \> 145 mmhg or dbp \> 95 mmhg) * severe liver disability (2.5-fold the normal high range value for alt, ast) * severe renal disability (scr \> 2.0mg/dl) * women who are pregnant, lactating, planning a pregnancy or women of child-bearing age who do not agree to proper contraception * use of oral steroids, oral antibiotic or other immunosuppressants within the past 4 weeks * treated by systemic photochemotherapy within past 4 weeks * history of drug abuse * hypersensitivity to rubi fructus, houttuyniae herba, rehmanniae radix, betulae platyphyllae cortex * use of other investigational products within the past two months

Keywords: scorad atopic dermatits skin health
minimal invasive anterior approach versus trans-gluteal approach for hemi-arthroplasty in femoral neck fractures

Conditions: Femoral Neck Fracture

Summary: the aim of the study is to test the hypothesis that patients older than 60 years with a femoral neck fracture eligible for hemi-arthroplasty (ha) operated by an anterior minimal-invasive approach as compared to a standard lateral hardinge approach show better functional recovery postoperatively as measured by the "timed up and go"-test (tug).

ha via various well established approaches is the typical treatment for displaced femoral neck fractures in elderly patients. in the last decade, so called minimal-invasive surgery (mis) for the implantation of total hip arthroplasty (tha) has become popular and studies have demonstrated that mis is as safe as conventional approaches. our hypothesis is that femoral neck fracture patients may especially benefit from mis. to date, no published data exist comparing a hueter minimal-invasive anterior (amis) with a conventional trans-gluteal hardinge approach (clas) for ha. geriatric patients presenting at the university hospital basel (uhbs) with a femoral neck fracture eligible for ha are randomly assigned to the minimal-invasive or conventional group. in both groups ha will be performed using the same implants. postoperatively patients will be followed-up continuously until discharge from our hospital (with 7 days as expected average duration of postoperative hospital stay) with a first functional status assessment on day 5. further follow-up is planned at week 3 and 6, 3 months and one year postoperatively.

Eligibility criteria:
inclusion criteria: * age of 60 years or more, ambulatory with/without walking aids before trauma * femoral neck fracture eligible for hemi-arthroplasty in accordance with the algorithm for femoral neck fracture patients used at the university hospital basel * informed consent exclusion criteria: * refusal of consent by the patient or legal representatives to participate in the study * more than one fracture * suspicion of a pathological fracture in the context of known or unknown malignancy * previous surgery of the proximal femur on the same side * follow-up not possible (tourist etc.)

Keywords: hip fracture hemiarthroplasty endoprosthesis elderly minimally invasive surgery anterior approach geriatric patients
reconstitution with pimecrolimus cream 1% of steroid-damaged skin in adults with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: topical steroid use may lead to skin deterioration and spider veins. this study will examine long-term management of atopic dermatitis (ad) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of steroid-damaged skin and disease control.


Eligibility criteria:
inclusion criteria: * clinically diagnosed ad * almost clear to mild ad (local iga \[target lesions face and cubital areas\] score of 1-3) * clinically (i.e. to the unaided eye) evident skin atrophy due to long-term topical steroid use * dermatophot score (dps - composed of skin atrophy and telangiectasia) of 4-6 on at least two target areas exclusion criteria: * phototherapy or systemic therapy known or suspected to have an effect on ad within 4 weeks prior to study entry * topical therapy known or suspected to have an effect on ad within 7 days prior to study entry or systemic corticosteroids within 4 weeks prior to study entry * clinical conditions other than ad that according to investigator can interfere with the dermatophot evaluation

Keywords: pimecrolimus, skin atrophy, dermoscopy, atopic dermatitis, eczema
life-long monitoring of diabetes mellitus in veneto region

Conditions: Diabetes Mellitus, Type 2

Summary: to evaluate whether patients with type 2 diabetes mellitus can be followed by simplified, centralized and large scale tele-monitoring of blood glucose levels, and whether this intervention produces health and economic benefits when introduced without major changes to the existing organization of a large treatment care center.

the study is designed to evaluate the impact of telemonitoring on the management of diabetes mellitus compared with outpatient usual care. from a clinical point of view, the measurements of hba1c will be taken to assess glycaemic control and the trial will allow to investigate how telemonitoring contributes to improve diabetes mellitus patients health-related quality of life and reduct the access to hospital facilities (re-hospitalizations, bed-days, specialistic and er visits) and the anxiety about health conditions. a cost-effectiveness and cost-utility analysis will be carried out in order to determine if and how telemonitoring helps to limit the healthcare expenditure. the evaluation will deal also with organizational changes and task shift due to telemonitoring introduction and patients and professionals perception towards the service.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes * hba1c \> 53 mmol/mol (7.0 % according to ngsp) * capability to use the devices provided * being cognitively able to participate * capability of filling in questionnaires in german or greek or italian language * absence of severe comorbidity prevalent on diabetes with life expectancy \< 12 months exclusion criteria: * pregnancy

Keywords: telemonitoring telemedicine diabetes mellitus
use of rhythmic auditory cueing during bilateral training of the upper extremities in stroke patients

Conditions: Hemiplegia, Spastic

Summary: the purpose of the study is to determine the effect of rhythmic auditory cueing with bilateral arm training on upper limb functions in stroke patients.

arm and hand movement problems are major contributors to disability in patients after stroke. in fact, only 5% of adults regain full arm function after stroke, and 20% regain no functional use. hence, alternative strategies are needed to reduce the long-term disability and functional impairment from upper limb hemiparesis. to solve problems concerning upper limb dysfunction related to stroke, various treatment methods have been used in several previous studies. rhythmic auditory stimulation has been reported as an effective intervention for improving movement in the affected extremities of stroke patients. to the best of our knowledge, no mentioned previous studies evaluating the effect of rhythmic auditory cueing with bilateral arm training using functional exercises on upper extremity impairment in patients with stroke in egypt are reported. so, this study aims to determine the effect of rhythmic auditory cueing with bilateral arm training on upper limb functions in patients with stroke.

Eligibility criteria:
inclusion criteria: 1. thirty patients with ischemic stroke from both sexes will be included. 2. patients will have stroke for the first time. 3. the age of patients will range from 45 to 60 years. 4. duration of illness will be from six months to eighteen months. 5. the degree of spasticity will ranged from 1 to 1 + grade according to the modified ashworth scale. 6. patients will have moderate arm motor impairment (between 30 and 49 scores) according to fugl-meyer (fm) arm section scale. 7. the affected upper extremity will be the dominant side. 8. patients will be able to sit and maintain balance in a sitting position. exclusion criteria: * the patients will be excluded if they have: 1. visual or auditory deficits. 2. perceptual disorders. 3. any surgical interventions in the upper extremities limiting the range of motion. 4. aphasia or apraxia. 5. musculoskeletal or neurological impairment of the unaffected upper extremity.
genetics of wilms' tumor and/or the associated conditions of aniridia, hemihypertrophy, and genitourinary anomalies

Conditions: Wilms' Tumor; Aniridia

Summary: the goal of this clinical research study is to collect information and blood samples to try to learn why some people develop cancers and tumors, why some families have more cancers than others, and whether certain genes or regions of dna (the genetic material of cells) affect a person's risk of getting cancer. this is an investigational study. up to 1500 patients and family members will take part in this study. all will be enrolled at md anderson.

if you choose to take part in this study, blood (about 10 teaspoons) will be drawn for genetic testing. the blood may be drawn more than 1 time, depending on how much blood is drawn at the first visit, and if you are available for more blood draws. if this is the case, your doctor will discuss any extra blood draws with you. for small children (less than 5 years old), about 2 teaspoons will be drawn. children who are 5 years old or older will not have more than 3 teaspoons drawn. you will complete a questionnaire about your medical history and family medical history. the questionnaire should take about 1 hour to complete. the study staff will also review your medical records. you will be asked to allow the study staff to collect any of your tissue (whether healthy or cancerous) that is leftover from surgeries performed as part of your standard care. this may be from any past or future surgeries or any tissue being stored at md anderson or elsewhere. no new surgeries or biopsies will be performed for this study. before your information, tissue samples, and/or bodily fluids can be used for research, the people doing the research must get specific approval from the institutional review board (irb) of md anderson. the irb is a committee made up of doctors, researchers, and members of the community. the irb is responsible for protecting the participants involved in research studies and making sure all research is done in a safe and ethical manner. all research done at md anderson, including research involving your information, tissue samples, and/or bodily fluids, must first be approved by the irb. you may be contacted either by phone or mail 1 time a year, so that the study staff can update your medical history and information. if contacted by phone, this call should last about 30 minutes.

Eligibility criteria:
inclusion criteria: 1. patients with familial and sporadic wilm's tumor, genitourinary anomalies, beckwith-wiedemann hemihypertrophy and/or aniridia, and family members of patients. exclusion criteria: 1. patients who do not meet inclusion eligibility criteria are excluded.

Keywords: wilms' tumor genitourinary anomalies beckwith-wiedemann hemihypertrophy aniridia questionnaire
controlled study of ono-2506po in patients with parkinson's disease in japan

Conditions: Parkinson's Disease

Summary: the purpose of this study is to evaluate the efficacy and safety of ono-2506po in patients with parkinson's disease


Eligibility criteria:
inclusion criteria: 1. diagnosis of parkinson's disease 2. stage 2 - stage 4 of revised hoehn \& yahr severity score 3. taking l-dopa/dci without changing dose and regimen 4. having motor complication 5. other inclusion criteria as specified in the study protocol exclusion criteria: 1. previous participation in ono-2506po or ono-2506 protocol 2. previous brain surgery for parkinson's disease 3. presence or history of serious cardiac disease 4. other exclusion criteria as specified in the study protocol

Keywords: ono-2506po, parkinson's disease
combination immunotherapy in colorectal cancer

Conditions: Colorectal Neoplasms

Summary: this is a pilot study to see whether a combination of two investigational drugs that target the immune system can be given to people with colorectal cancer before surgically removing the tumor. this study is also being done to see what side effects this combination of drugs has and what effect they have on colorectal cancer. the two monoclonal antibodies are balstilimab, a programmed cell death protein 1 (pd-1) inhibitor, and botensilimab, a cytotoxic t lymphocyte-associated protein 4 (ctla-4) inhibitor. this study has 3 cohorts. participants in cohort a will receive a total of 2 doses of balstilimab and a single dose of botensilimab, both given intravenously (iv), before surgery. participants in cohort b and c will receive a total of 4 doses of balstilimab and a single dose of botensilimab, both given intravenously (iv), before surgery. participants in cohort c must have dmmr/msi-high colorectal cancer.

this is a pilot study to assess the feasibility, safety, and efficacy of using a combination of a programmed cell death protein 1 (pd-1) inhibitor (balstilimab) and cytotoxic t lymphocyte-associated protein 4 (ctla-4) inhibitor (botensilimab) in the neoadjuvant setting in patients with colorectal cancer, prior to resection. this is a single-center, open-label, pilot study in which patients will receive 2 or 4 doses of intravenous (iv) balstilimab (each dose approximately 2 weeks apart), and a single dose of botensilimab iv, prior to resection in patients with colon cancer. following surgical resection, participants will return to the clinic for 1-2 post-op follow-up visits.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * histologically, cytologically, or clinically confirmed adenocarcinoma of the colon or rectal cancer as long as there is no plans for neoadjuvant radiation for the patients with rectal cancer. note: patients can enroll in cohort b while awaiting mismatch repair testing results. if noted to be dmmr/msi-high, they would be still considered evaluable and moved to cohort c. * if capable of becoming pregnant, or getting someone else pregnant, must be willing to use highly effective contraception from screening period through 90 days following the last dose of study drug exclusion criteria: * metastatic cancer (cancer that has spread to other parts of the body) * previous treatment with immune checkpoint inhibitors targeting ctla-4, pd-1 or pd-l1 * currently participating in another study and receiving a study drug * history of severe allergic reactions to immunotherapies * pregnant or breastfeeding * active infection requiring treatment * on immunosuppressive medications * active cardiovascular disease, such as stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure, or serious uncontrolled cardiac arrhythmia requiring medication that may prevent surgery participants in cohort c must be dmmr/msi-high.

Keywords: immunotherapy colorectal cancer pd-1 ctla-4
extra-fine formoterol/beclomethasone in asthmatic crisis

Conditions: Asthma; Asthmatic Crisis

Summary: the purpose of this study is to determine whether extra fine formoterol/beclomethasona are more effective in the treatment of asthmatic crisis when added to conventional treatment compared with conventional treatment alone.

inhaled corticosteroids still the cornerstone in treatment of stable asthma, while bronchodilators and systemic steroids are in asthmatic crisis. asthmatic exacerbations are events occurring in the natural course of the disease, require a change in actual medication and they are associated with risks of complications producing important economic costs. some is known about non-genomic effects of inhaled corticosteroids, making possible, at least in theory, having a positive effect on treatment of a crisis. on the other hand, formoterol has been shown to have a rapid beginning of action (3 minutes), persisting its effect during 12 hours and it has been shown to be as effective as albuterol in the treatment of a crisis. the development of extra-fine particles has allowed reaching more distal zones in the lungs producing more deposition of the drug, which as well decrease adverse effects are lesser doses of the drug are needed. according to that, aims of this work is to determine whether extra-fine formoterol/beclomethasona are more effective in the treatment of asthmatic crisis when added to conventional treatment compared with conventional treatment in terms of pulmonary function, symptoms, inflammation markers and rates of hospitalization.

Eligibility criteria:
inclusion criteria: * previous asthma diagnosis by physician * spirometry with quality grade a, b or c * presenting with asthmatic crisis in emergency room exclusion criteria: * imminent respiratory arrest * respiratory comorbidities (copd, cystic fibrosis, interstitial lung disease, pneumothorax, bronchiectasis) * use of systemic steroids in 3 months previous * allergy to steroids * peripheral capillary oxygen saturation (spo2) less than 88%.

Keywords: formoterol/beclomethasone in asthmatic crisis asthmatic crisis treatment
clinical investigation of the wavelight® ex500 excimer laser

Conditions: Hyperopia; Hyperopic Astigmatism

Summary: the purpose of this study is to collect efficacy and safety data on the wavelight ex500 excimer laser system for the correction of hyperopia with and without astigmatism by laser in situ keratomileusis (lasik) treatment.

qualified subjects will receive lasik treatment in both eyes and be followed for 1 year. subjects will be asked to attend a total of 9 visits (screening, surgery, day 1, week 1, month 1, month 3, month 6, month 9, and month 12). total expected duration of subject participation is approximately 1 year.

Eligibility criteria:
key inclusion criteria: * intended to treat bilaterally; * hyperopia with or without astigmatism as specified in the protocol; * stable vision as specified in the protocol; * other protocol-defined inclusion criteria may apply. key exclusion criteria: * glaucoma; * cataracts; * previous eye surgery; * intent to have monovision treatment; * other protocol-defined exclusion criteria may apply.

Keywords: lasik refractive errors
efficacy and safety of evogliptin add-on to metformin in patients with type2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: this is a randomized, double-blind, active-controlled, phase iii clinical trial to investigate the efficacy and safety of evogliptin when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

1. evogliptin 5mg group: administration with evogliptin 5mg add-on to metformin for 0-52 weeks. 2. sitagliptin 100mg group: administration with sitagliptin 100mg add-on to metformin for 0-24 weeks, and with evogliptin 5mg add-on to metformin for 24-52 weeks.

Eligibility criteria:
inclusion criteria: * subjects with 6.5%≤hba1c≤11.0% at screening * subjects treated with 1,000mg/day or higher dose of metformin for at least 6 weeks prior to screening among people treated with metformin monotherapy for at least 12 weeks before screening * subjects with 20kg/m2≤bmi≤40kg/m2 at screening exclusion criteria: * subjects with fasting plasma glucose≥270mg/dl at screening * patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus * subjects with history of myocardial infarction, cerebral infarction within 6 months prior to screening * subjects with alt and ast 2.5 times or higher than upper normal range
patient and physician benefit/ risk preferences for treatment of mpc in hong kong: a discrete choice experiment

Conditions: Prostate Cancer

Summary: the objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in physician and prostate cancer patients from different stages of disease.


Eligibility criteria:
inclusion criteria: * aged 18 years or older, * diagnosis of metastatic prostate cancer within 5 years, * able to read and write, * accepting and signing the informed consent exclusion criteria: * if patients are unable to complete the survey by themselves due to physical or psychological reasons, * deemed ineligible by treating physicians if patients are unable to complete the survey by themselves due to physical or psychological reasons, * deemed ineligible by treating physicians
h19 in acute lymphoblastic leukemia.

Conditions: Acute Lymphoid Leukemia

Summary: * study the expression level of h19 gene in the samples from all patients by real-time pcr. * correlate the expression level of h19 gene with the clinical presentation and laboratory data of those patients.

acute lymphoblastic leukemia (all) is the most common cancer affecting children and adolescents (zeng xl et al, 2023). all is a haematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors (hong z et al, 2021). it arises from b- or t-lineage lymphoid progenitors: b-cell-precursor all (b-all) and t-cell all (t-all) (brady sw et al., 2022). rrelapse in all is the fundamental cause of treatment failure in 15-20% of patients (hulleman e et al, 2009). therefore, the exploration of novel functional molecules that play a role in all pathogenesis could be effective therapeutic targets for this disease (asadi m et al, 2023). long non-coding rnas (lncrnas) are non-protein coding transcripts longer than 200 nucleotides (kopp f et al, 2018). h19 was the first lncrna to be discovered and submitted for genomic imprinting (yoshimura h et al, 2018). it has a role in embryogenesis and tumorigenesis (yoshimura h et al, 2014). it also has an indispensable role in enhancing cell proliferation, differentiation, migration, invasion, and chemo resistance (li y et al, 2020). recent evidence has shown that h19 is an oncogene and is overexpressed in breast, liver, endometrial, lung, cervical, and esophageal cancers (asadi m et al, 2023). a similar pattern of h19 expression was observed in various types of leukemias, including chronic myeloid leukemia (cml) (morlando m et al, 2015) and acute myeloid leukemia (aml) (zhang tj et al, 2018).

Eligibility criteria:
inclusion criteria: * newly diagnosed all patients. exclusion criteria: - 1-presence of other haematological disorders, history of other malignancies or relapsed all. 2-patients under chemotherapy or radiotherapy.